申请人:Sawai Pharmaceutical Co., Ltd.
公开号:US04634777A1
公开(公告)日:1987-01-06
Compounds of the general formula: ##STR1## wherein A and B are both hydrogen, or one of A and B is a group (G) of the formula: ##STR2## and the other is a group R.sup.5 wherein R.sup.1 is an aryl group or a heterocyclic group, both of them being optionally substituted, and R.sup.4 and R.sup.5 are both hydrogen or together form a single chemical bond, R.sup.2 and R.sup.2 ' are independently hydrogen, halogen, nitro, lower alkyl or lower alkoxy, and R.sup.3 and R.sup.3 ' are independently carboxy or its functional derivative, with the proviso that (a) when A and B are both hydrogen, then R.sup.2 and R.sup.2 ' cannot be both hydrogen, and, where applicable, pharmaceuticably acceptable salts thereof are hyaluronidase inhibitors, and useful as anti-allergic agent and anti-ulcerous agent. Among the compound (I'), those wherein when one of A and B is the group (G) and the other is the group R.sup.5 wherein R.sup.4 and R.sup.5 together form a single chemical bond, R.sup.1 is unsubstituted aryl and R.sup.2 and R.sup.2 ' are both hydrogen, then R.sup.3 and R.sup.3 ' are independently carboxy or its functional derivative other than methyl ester, are novel.
通式为:##STR1##其中A和B都是氢,或者A和B中的一个是公式为:##STR2##的基团(G),另一个是基团R.sup.5,其中R.sup.1是芳基或杂环基团,两者都可以选择性地被取代,而R.sup.4和R.sup.5都是氢或者一起形成单一化学键,R.sup.2和R.sup.2 '分别是氢、卤素、硝基、低烷基或低烷氧基,而R.sup.3和R.sup.3 '分别是羧基或其功能衍生物,但是当A和B都是氢时,则R.sup.2和R.sup.2 '不能都是氢,其中适用的药物学上可接受的盐是透明质酸酶抑制剂,并且作为抗过敏剂和抗溃疡剂有用。在化合物(I')中,当A和B中的一个是基团(G),另一个是基团R.sup.5,其中R.sup.4和R.sup.5一起形成单一化学键,R.sup.1是未取代的芳基,而R.sup.2和R.sup.2 '都是氢时,则R.sup.3和R.sup.3 '分别是羧基或其功能衍生物,但不包括甲酯,是新颖的。